Stockscreener 앱 받기
1.76
7.98%
0.13
시장 영업 전:
1.79
0.03
+1.70%
Bioatla Inc 주식(BCAB)의 최신 뉴스
BioAtla Inc (BCAB)’s financial ratios: A comprehensive overview - The Dwinnex
A new trading data show BioAtla Inc (BCAB) is showing positive returns. - SETE News
XTX Topco Ltd Trims Stock Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Michael Burry just bought 633,959 shares in this $1 penny stock - Motley Fool UK
Scion Asset Management LLC Purchases Shares of 633,959 BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Wall Street SWOT: BioAtla stockInnovative cancer therapy faces pivotal year - Investing.com
BCAB’s valuation metrics: A comprehensive analysis - US Post News
Scion Asset Management LLC Purchases Shares of 633,959 BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
Century Therapeutics (NASDAQ:IPSC) & BioAtla (NASDAQ:BCAB) Financial Comparison - Defense World
BioAtla and Context Therapeutics Forge Strategic Agreement for Cancer Treatment Development - MSN
BioAtla and Context Therapeutics Forge Strategic Agreement for Cancer Treatment Development - MyChesCo
Analyzing Bio-Techne Corp (TECH) After Recent Trading Activity - Knox Daily
BlackRock Capital Allocation Term Trust (NYSE:BCAT) Major Shareholder Saba Capital Management, L.P. Sells 33,209 Shares - Defense World
BioAtla out-licenses T cell therapy in $134 million deal - The Pharma Letter
(BTMD) Technical Pivots with Risk Controls - Stock Traders Daily
BioAtla licenses cancer drug candidate to Context Therapeutics By Investing.com - Investing.com Canada
BioAtla licenses cancer drug candidate to Context Therapeutics - Investing.com
Dawson James downgrades BioCardia Inc. (BCDA) stock to a Neutral - Knox Daily
Context Therapeutics signs second multimillion-dollar licensing deal in 3 months - The Business Journals
BlackRock Capital Allocation Term Trust (NYSE:BCAT) Major Shareholder Sells $245,706.93 in Stock - Defense World
SickKids names FCB Canada new AOR - Strategy Online
Context builds up bank of bispecific antibodies with up to $133M biobucks deal for BioAtla asset - Fierce Biotech
BioAtla licenses cancer drug candidate to Context Therapeutics - Investing.com India
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody - GlobeNewswire
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody - StockTitan
Massachusetts Financial Services Co. MA Has $741,000 Holdings in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Acadian Asset Management LLC Sells 80,157 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Benjamin Edwards Inc. Decreases Stake in Bank of America Co. (NYSE:BAC) - MarketBeat
BlackRock Capital Allocation Term Trust (NYSE:BCAT) Major Shareholder Saba Capital Management, L.P. Sells 15,894 Shares - Defense World
BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 6.3% in August - Defense World
BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 6.3% in August - MarketBeat
Analyzing Genocea Biosciences (NASDAQ:GNCA) and BioAtla (NASDAQ:BCAB) - Defense World
BioAtla (NASDAQ:BCAB) Stock Rating Reaffirmed by JMP Securities - Defense World
Balance Sheet Insights: BioAtla Inc (BCAB)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
BCAB’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
BioAtla reports promising Phase 2 trial results for cancer drug By Investing.com - Investing.com Canada
Head to Head Contrast: Genocea Biosciences (NASDAQ:GNCA) vs. BioAtla (NASDAQ:BCAB) - Defense World
BioAtla reports promising Phase 2 trial results for cancer drug - Investing.com
BioAtla reports promising Phase 2 trial results for cancer drug By Investing.com - Investing.com UK
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 Euro - Yahoo Finance
JMP Securities Reiterates Market Outperform Rating for BioAtla (NASDAQ:BCAB) - MarketBeat
Examining BioAtla Inc (BCAB) more closely is necessary - US Post News
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting - StockTitan
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting - Yahoo Finance
BioAtla Inc (BCAB) Stock: Navigating Drops and Gains - The InvestChronicle
Should investors be concerned about BioAtla Inc (BCAB)? - US Post News
Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky - Yahoo Finance
Daily Market Movement: BioAtla Inc (BCAB) Sees a -2.75 Decrease, Closing at 1.77 - The Dwinnex
Short Interest in BioAtla, Inc. (NASDAQ:BCAB) Rises By 18.8% - MarketBeat
BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Stocks of BioAtla Inc (BCAB) are poised to climb above their peers - SETE News
Financial Fitness Check: Examining BioAtla Inc (BCAB)’s Key Ratios - The Dwinnex
Can you still get a good price for BioAtla Inc (BCAB) Shares at this point? - US Post News
Holdings of BioAtla Inc (BCAB) are aligned with the stars - SETE News
BioAtla Inc’s Market Journey: Closing Weak at 1.89, Down -0.53 - The Dwinnex
BTIG reaffirms 'Buy' on BioAtla stock ahead of key 2024 milestones - Investing.com India
BTIG reaffirms 'Buy' on BioAtla stock ahead of key 2024 milestones - Investing.com
Is it possible to buy BioAtla Inc(BCAB) shares at a good price now? - US Post News
Price T Rowe Associates Inc. MD Acquires Shares of 12,791 BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Vanguard Group Inc. Increases Stock Holdings in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BCAB Stock: Exploring BioAtla Inc’s Growth - The InvestChronicle
BioAtla Inc (BCAB)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Michael Burry's Scion Asset sheds Safe Bulkers, adds Hudson Pacific, others in Q2 - Seeking Alpha
BioAtla Up 14% as Burry's Scion Asset Management Reports Stake in 13F - MarketWatch
Michael Burry Raises Alibaba Stake, Cuts Stock Portfolio in Half - BNN Bloomberg
Closing Strong: BioAtla Inc (BCAB) Ends at 1.39, Down -5.44 from Last Close - The Dwinnex
Earnings call: BioAtla reports progress and strategic focus in Q2 2024 - Investing.com
BioAtla, Inc. (NASDAQ:BCAB) Q2 2024 Earnings Call Transcript - Insider Monkey
BioAtla (NASDAQ:BCAB) Announces Earnings Results - Defense World
BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript - Seeking Alpha
BioAtla (NASDAQ:BCAB) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
0.05%
4.86%
자본화:
|
볼륨(24시간):